证券代码：603882 证券简称：金域医学 公告编号：2025-030 (二)股东会召开的地点：广州市国际生物岛螺旋三路 10 号金域医学总部大楼 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 642 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 211,205,443 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份总数的 | 45.5912 | | 比例（%） | | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 广州金域医学检验集团股份有限公司 2024年年度股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、会议召开和出席情况 (一)股东会召开的时间：2025 年 6 月 9 日 二、议案审议情况 (一)非累积投票议案 1、议案名称：广州金域医学检验集团股份有限公司 2024 年度董事会工作报告 审议结果：通过 表决 ...

北京市中伦律师事务所 关于广州金域医学检验集团股份有限公司 2024 年年度股东会的 法律意见书 二〇二五年六月 北京市朝阳区金和东路 20 号院正大中心 3 号南塔 22-31 层 邮编：100020 22-31/F, South Tower of CP Center, 20 Jin He East Avenue, Chaoyang District, Beijing l00020, P.R. China 电话/Tel : +86 10 5957 2288 传真/Fax : +86 10 6568 1022/1838 www.zhonglun.com 北京市中伦律师事务所 关于广州金域医学检验集团股份有限公司 2024 年年度股东会的 法律意见书 在本法律意见书中，本所律师仅对本次股东会的召集、召开程序、出席本次 股东会人员和召集人的资格、会议表决程序及表决结果是否符合《公司法》《证 券法》《股东会规则》等法律、法规、规范性文件及《公司章程》的相关规定发 - 1 - 法律意见书 表意见，不对会议审议的议案内容以及该等议案所表述的事实或数据的真实性及 准确性发表意见。 本法律意见书仅供公司本次股东会相关事项的 ...

证券代码：603882 证券简称：金域医学 公告编号：2025-030 广州金域医学检验集团股份有限公司 2024年年度股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、会议召开和出席情况 (一)股东会召开的时间：2025 年 6 月 9 日 (二)股东会召开的地点：广州市国际生物岛螺旋三路 10 号金域医学总部大楼 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 642 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 211,205,443 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份总数的 | 45.5912 | | 比例（%） | | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议由董事会召集，公司董事长梁耀铭先生主持，本次会议的召集、召 开及表决形式均符合《公司法》及《公司章程》的规定。 二、议案审议情况 ...

Core Viewpoint - The company, Guangzhou Kingmed Diagnostics Group Co., Ltd., has responded to the Shanghai Stock Exchange's inquiry regarding its 2024 annual report, addressing issues related to cash management, bank borrowings, asset impairments, and related party transactions. Group 1: Cash Management - As of December 31, 2024, the company's cash balance was CNY 2.433 billion, with restricted cash of CNY 11 million and interest income of CNY 23 million. Long-term borrowings increased by 92.42% to CNY 514 million [1][2][12] - The company reported a cash yield of 1.15%, which is higher than the bank's current interest rate, primarily due to the presence of certain agreed deposits [4][6] - The company maintains a significant cash reserve to manage short-term payment pressures and to respond to potential operational risks due to economic fluctuations [7] Group 2: Bank Borrowings - New bank borrowings during the reporting period were primarily used for capital expenditures, working capital, and repaying maturing debts. The company has a strategy to secure long-term loans to support significant capital projects [7][8] - The increase in long-term borrowings is justified by the need for funding important capital projects and maintaining a stable relationship with banks [7][8] Group 3: Asset Impairments - The company reported a significant impairment loss on accounts receivable amounting to CNY 619 million, with accounts receivable totaling CNY 4.396 billion, representing 60.07% of current assets [12][13] - The company has implemented measures to improve the collection of accounts receivable, including establishing a dedicated collection team and utilizing digital tools for monitoring [15][16] - Fixed assets worth CNY 506 million were scrapped, with accumulated depreciation of CNY 355 million, due to inefficiencies and inability to meet operational needs [17][18] Group 4: Related Party Transactions - The company engaged in significant transactions with Guangzhou Jinmianli Pharmaceutical Technology Co., Ltd., with procurement amounting to CNY 52 million and sales of CNY 64 million, reflecting substantial year-on-year growth [26][30] - The increase in transaction amounts is attributed to the transfer of equity in Jinmianli, which led to a change in the nature of the business relationship [29][30] - The transactions are deemed necessary for operational continuity and are conducted at fair market prices, with no indications of profit transfer [33][36] Group 5: Operating Performance - The company reported a revenue of CNY 7.190 billion for 2024, a decrease of 15.81% year-on-year, with a net loss of CNY 381 million compared to a profit of CNY 643 million in the previous year [37][44] - The decline in revenue is attributed to market demand slowdown, increased fixed cost allocation, and the impact of policy changes in the healthcare sector [40][41] - The company’s gross margin decreased from 36.48% in 2023 to 33.15% in 2024, reflecting the challenges faced in the current market environment [42][44]

数字经济时代，数据作为关键生产要素价值日益凸显。据6月6日国家数据局消息，我国将在北京、浙 江、安徽等地部署建设10个国家数据要素综合试验区，支持各地在培育经营主体、繁荣壮大数据市场等 方面开展先行先试，全面释放实体经济和数字经济融合效能。 全联并购公会信用管理委员会专家安光勇在接受《证券日报》记者采访时表示："当前我国数据市场建 设还处于起步阶段，顶层政策与试验区建设为数据要素市场按下'加速键'。要最大程度释放数据要素价 值，需质量、合规、场景、资本、人才五路并进，把数据从'成本中心'转变为跨周期增长的'乘数效应发 动机'。" 政策红利持续释放 数据要素的市场化、价值化，受到政府的高度重视。5月26日下午，国家数据局党组书记、局长刘烈宏 主持召开培育全国一体化数据市场座谈会。会议提出，要深入贯彻落实党中央、国务院决策部署，大力 推动数据要素市场化价值化，让数据要素价值加快"显性化"。市场化是手段，价值化是目的。既要积极 推动公共数据开发利用，持续发力数字政府建设和经济社会发展；又要积极推动企业用数创新，让数据 要素价值体现在企业降本增效里，体现在培育新质生产力中，体现在赋能经济社会高质量发展上。 此前，支持 ...

立信会计师事务所（特殊普通合伙） 关于广州金域医学检验集团股份有限公司 2024年年度报告的事后审核问询函的回复 信会师函字[2025]第ZA180号 上海证券交易所： 贵所出具的《关于广州金域医学检验集团股份有限公司2024年年度报告 的事后审核问询函》（上证公函【2025】0547号）（以下简称"问询函"）已 收悉。立信会计师事务所（特殊普通合伙）（以下简称"我们"或"年审会计 师"）作为广州金域医学检验集团股份有限公司（以下简称"公司"或"金域 医学"）2024年审会计师，对问询函中提到的需要会计师发表意见的问题进 行了认真核查，现回复如下： 注:以下除特别注明外，本函所使用的名词释义与金域医学2024年年报 一致；回复数值若出现总数与各分项数值之和尾数不符的情况，均为四舍 五入原因造成。 回复第 1 页 问题1、关于货币资金相关情况。 年报显示，报告期末公司货币资金余额24.33亿元，其中受限资金0.11亿 元，利息收入0.23亿元。负债端，长期借款同比增长92.42%至5.14亿元，租赁 负债1.18亿元。此外，公司其他应收款0.83亿元，其中往来款0.28亿元。 请公司补充披露：（1）列示前五大存 ...

年报显示，报告期末公司货币资金余额24.33亿元，其中受限资金0.11 亿元，利息收入0.23亿元。负债端，长期借款同比增长92.42%至5.14亿元， 租赁负债1.18亿元。此外，公司其他应收款0.83亿元，其中往来款0.28亿元。 请公司补充披露：（1）列示前五大存款账户具体存放银行名称、对应金 额、利率水平及期限，分析利息收入与货币资金规模的匹配性，并说明上述 货币资金是否存在其他权利限制或潜在限制性安排；（2）报告期内新增银行 借款的用途、抵押担保情况、利率及还款安排，并结合所在行业特点和历史 经营数据，日常营运资金需求及其近年随收入规模的变化情况、实际可支配 现金、投融资安排及未来资金缺口等，说明货币资金规模合理性，以及在货 币资金充裕的情况下，长期借款大幅增长的原因及合理性；（3）租赁负债对 应资产的具体内容、融资对象、租赁期限及利息成本；（4）其他应收款中往 第1页 证券代码：603882 证券简称：金域医学 公告编号：2025-029 广州金域医学检验集团股份有限公司 关于上海证券交易所对公司 2024 年年度报告的事后 审核问询函的回复公告 本公司董事会及全体董事保证本公告内容不存在任何虚假 ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5] Core Insights - The blood purification device industry is benefiting from an aging population and increasing treatment penetration rates, with hemodialysis being the primary treatment for end-stage renal disease (ESRD) [2][12] - The domestic substitution trend in the blood purification device industry is accelerating, with local brands gradually rising to compete with foreign brands [2][33] - The market for blood purification devices is expected to grow significantly, driven by the increasing number of ESRD patients and the low treatment penetration rate in China compared to developed countries [17][19] Summary by Sections Market Performance - The pharmaceutical sector outperformed the overall market, with a 2.21% increase in the biopharmaceutical sector, while the total A-share market declined by 0.05% [1][60] - The TTM price-to-earnings ratio for the biopharmaceutical sector is 34.03x, which is at the 69.61% percentile of the historical valuation over the past five years [1][67] Industry Analysis - The global ESRD patient population is projected to grow from 1113.86 million in 2023 to 1328.60 million by 2027, with a compound annual growth rate (CAGR) of 4.51% [17] - In China, the number of ESRD patients receiving dialysis treatment is significantly lower than in developed countries, indicating substantial growth potential for treatment penetration [19][30] Competitive Landscape - Foreign brands dominate the blood purification device market, with companies like Fresenius and Baxter holding significant market shares, but local brands are increasingly gaining ground [33][37] - Major domestic players include Weigao Blood Purification, Shanda Mountain, and Jianfan Biological, which are expanding their market presence through innovation and product development [33][41][45] Company Forecasts and Ratings - Major companies in the sector, such as Mindray Medical and WuXi AppTec, are rated as "Outperform" with strong projected earnings growth over the next few years [4][71] - Weigao Blood Purification is expected to generate revenue of 36.04 billion yuan in 2024, with a leading market share in blood purification devices [38][41]

Core Viewpoint - The company is preparing for its 2024 annual shareholders' meeting, where various proposals will be discussed, including the annual report, auditor reappointment, and compensation plans for management and supervisors. The company has faced significant financial challenges in 2024, with a notable decline in revenue and net profit compared to the previous year [8][24]. Group 1: Meeting Details - The annual shareholders' meeting is scheduled for June 9, 2025, at 14:30, with both on-site and online voting options available for shareholders [1][2]. - The meeting will cover eight proposals, including the annual report and the reappointment of the auditing firm for 2025 [5][6]. Group 2: Financial Performance - In 2024, the company reported a revenue of approximately 7.19 billion yuan, a decrease of 15.81% from 2023 [20]. - The net profit attributable to shareholders was -381.24 million yuan, representing a decline of 159.26% year-on-year [20][24]. - The company’s basic earnings per share for 2024 were -0.82 yuan, down 159.42% from 1.38 yuan in 2023 [20]. Group 3: Operational Strategy - The company aims to enhance operational efficiency by focusing on profit, cash flow, and quality revenue, while also innovating its marketing strategies [13]. - A significant emphasis will be placed on digital transformation and data governance to optimize costs and improve operational efficiency [13][14]. Group 4: Governance and Compliance - The company has established a comprehensive internal control system to ensure effective management and compliance with regulations [18]. - The supervisory board has conducted thorough oversight of the company's financial management and compliance with legal requirements, finding no violations [17][19]. Group 5: Future Outlook - The company plans to reinvest retained earnings into development rather than issuing dividends, reflecting a focus on long-term growth [24][25]. - The board has proposed to continue the engagement with the auditing firm, Lixin, for the 2025 fiscal year, highlighting its established reputation and expertise [27][28].

二〇二五年六月 广州金域医学检验集团股份有限公司 2024 年年度股东会会议资料 目录 | 广州金域医学检验集团股份有限公司 2024 年年度股东会会议议程 | | | 3 | | --- | --- | --- | --- | | 广州金域医学检验集团股份有限公司 2024 年年度股东会会议须知 | | | 6 | | 议案一：广州金域医学检验集团股份有限公司 2024 年度董事会工作报告 | | | 8 | | 议案二：广州金域医学检验集团股份有限公司 2024 年度监事会工作报告 | | | 16 | | 议案三：广州金域医学检验集团股份有限公司 2024 年度财务决算报告 | | | 20 | | 议案四：广州金域医学检验集团股份有限公司 2024 年度利润分配预案 | | | 24 | | 议案五：广州金域医学检验集团股份有限公司 2024 年年度报告全文及摘要 | | | 26 | | 议案六：广州金域医学检验集团股份有限公司关于续聘 2025 | | 年度审计机构和内控审计 | | | 机构的议案 | | | 27 | | 议案七：广州金域医学检验集团股份有限公司关于确认公司董事、高级管理人员 ...